$23.25
2.04%
Nasdaq, Jul 18, 10:00 pm CET
ISIN
NL00150005Y4
Symbol
PHVS
Sector
Industry

Pharvaris NV Stock price

$23.25
+6.61 39.69% 1M
+4.89 26.61% 6M
+4.08 21.26% YTD
+5.18 28.64% 1Y
+0.06 0.24% 3Y
+3.25 16.23% 5Y
+3.25 16.23% 10Y
+3.25 16.23% 20Y
Nasdaq, Closing price Fri, Jul 18 2025
-0.49 2.04%
ISIN
NL00150005Y4
Symbol
PHVS
Sector
Industry

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$992.5m
Net debt
positive
Cash
$275.0m
Shares outstanding
54.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.8
Financial Health
Equity Ratio
91.9%
Return on Equity
-50.1%
ROCE
-70.6%
ROIC
-2,392.6%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-185.2m | $-203.9m
EBIT
$-185.5m | $-211.3m
Net Income
$-177.4m | $-197.9m
Free Cash Flow
$-157.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-53.3% | -20.6%
EBIT
-53.2% | -24.7%
Net Income
-43.6% | -26.8%
Free Cash Flow
-46.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.3
FCF per Share
$-2.9
Short interest
1.8%
Employees
83
Rev per Employee
$0.0
Show more

Is Pharvaris NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Pharvaris NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Pharvaris NV forecast:

15x Buy
88%
1x Hold
6%
1x Sell
6%

Analyst Opinions

17 Analysts have issued a Pharvaris NV forecast:

Buy
88%
Hold
6%
Sell
6%

Financial data from Pharvaris NV

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 56 56
44% 44%
-
- Research and Development Expense 129 129
58% 58%
-
-185 -185
53% 53%
-
- Depreciation and Amortization 0.36 0.36
20% 20%
-
EBIT (Operating Income) EBIT -186 -186
53% 53%
-
Net Profit -177 -177
44% 44%
-

In millions USD.

Don't miss a Thing! We will send you all news about Pharvaris NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pharvaris NV Stock News

Positive
Seeking Alpha
3 days ago
Pharvaris is a late-stage biopharma that specializes in the treatment of hereditary angioedema (HAE). They have only one drug in their pipeline, deucrictibant, of which they are making two oral formulations: an immediate-release capsule for acute attacks and a daily extended-release tablet. Phase 3 results for the immediate-release capsules (Rapide-3) are expected in Q4 2025.
Neutral
GlobeNewsWire
11 days ago
ZUG, Switzerland, July 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), updated the guidance for the disclosure of to...
Neutral
GlobeNewsWire
24 days ago
ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstra...
More Pharvaris NV News

Company Profile

Pharvaris NV is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Hans G. C. P. Schikan and Anne Lesage on September 30, 2015 and is headquartered in Leiden, Netherlands.

Head office Netherlands
CEO Berndt Modig
Employees 83
Founded 2015
Website pharvaris.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today